Kala Pharmaceuticals, Inc. (KALA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Visitors trend2W10W9M

16.93

-0.41

(-2.36%)

As of 10:46AM EST. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Fast Stochastic

View all chart patterns

Performance Outlook

Previous Close	17.34
Open	17.18
Bid	16.88 x 3000
Ask	17.00 x 1400
Day's Range	16.81 - 17.35
52 Week Range	3.54 - 97.00
Volume	36,030
Avg. Volume	2,560,786

Market Cap	31.676M
Beta (5Y Monthly)	-1.53
PE Ratio (TTM)	N/A
EPS (TTM)	-2.14
Earnings Date	Mar 27, 2023 - Mar 31, 2023
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	45.88

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for KALA

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Kala Pharmaceuticals, Inc.
Analyst Report: Regeneron Phars, IncRegeneron is a biopharmaceutical company focused on treatments for eye diseases, cancer, dermatitis, and rheumatoid arthritis. Founded in 1988, Regeneron has collaborated with Amgen, Procter & Gamble, Bayer, Sanofi, and Japan's Sumitomo Chemical. The company is a component of the S&P 500, has more than 10,900 employees worldwide, and is based in Tarrytown, New York.
Rating
Fair Value
Economic Moat
14 days agoArgus Research

All

Zacks
Kala Pharma (KALA) Is Considered a Good Investment by Brokers: Is That True?
The average brokerage recommendation (ABR) for Kala Pharma (KALA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
- Wall Street Bulls Look Optimistic About Visa (V): Should You Buy?
  Zacks
- Is Disney (DIS) a Buy as Wall Street Analysts Look Optimistic?
  Zacks
Zacks
Best Momentum Stocks to Buy for January 17th
RYAM, BUD and KALA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 17, 2022.
MarketWatch
Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment
Shares of Kala Pharmaceuticals Inc. (KALA) have rocketed higher in for three-straight sessions, toward a more-than 8-fold gain, since the biopharmaceutical company announced positive news regarding its treatment of persistent corneal epithelial defect (PCED). The stock exploded up 218.4% on Wednesday, after the Food and Drug Administration accepted the investigational new drug (IND) application for the PCED treatment, KPI-012, then rose 99.0% on Thursday. Kala’s stock is still down 44.8% year to date, while the iShares Biotechnology ETF (IBB) has slumped 14.9% and the S&P 500 (SPX) has shed 19.8%.